Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis [2] (multiple letters)

Annals of Neurology

Volumn 46, Issue 6, 1999, Pages 934-

  Upton Rice, M N ^a   Cudkowicz, M E ^a   Warren, L ^a   Mathew, R K ^a   Ren, J M ^a   Finklestein, S P ^a   Brown Jr , R H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; NEUROPROTECTIVE AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; FAMILIAL DISEASE; GENE MUTATION; INTRAPERITONEAL DRUG ADMINISTRATION; LETTER; MOTONEURON; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TRANSGENIC MOUSE;

EID: 0345504143     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199912)46:6<934::AID-ANA21>3.0.CO;2-0     Document Type: Letter

References (5)

1. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62
2. Ay I, Finkelstein S. Preclinical trials of basic fibroblast growth factor (bFGF) in animal models of stroke. In: Mattson M, ed. Neuroprotective signal transduction. Totown: Humana Press, 1998;111-118.
3. Gurney M, Cutting F, Zhai P, et al. Benefit of vitamin E, riluzole and gabapentin in a transgenic model of familial ALS. Ann Neurol 1996;39:147-157
4. Klivenyi P, Ferrante R, Matthew R, et al. Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat Med 1999; 5:347-350
5. Hottinger A, Fine E, Gurney M, et al. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur J Neurosci 1997;9:1548-1551